Evidence map›Paper›PMID 42204558›Full record

ArticleChinese medicine2026

6-Shogaol inhibits HSCs activation and liver fibrosis by regulating glycolytic reprogramming via targeting HIF-1α.

Junfa Yang, Min Shu, Hui Fang, Fan Yang, Jiahe Li, Yuansong Sun, He Li, Tao Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Junfa Yang *Department of Emergency Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China.
Min Shu *Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, School of Pharmaceutical Sciences, Anhui Medical University, Hefei, 230032, China.
Hui Fang *School of Basic and Science Medicine, Anhui Medical University, Hefei, 230032, China.
Fan Yang *Department of Ophthalmology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Jiahe LiInflammation and Immune Mediated Diseases Laboratory of Anhui Province, School of Pharmaceutical Sciences, Anhui Medical University, Hefei, 230032, China.
Yuansong SunDepartment of Emergency Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China.
He LiDepartment of Emergency Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China. lihe@ahmu.edu.cn.
Tao XuDepartment of Emergency Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China. xutao@ahmu.edu.cn.

Funding

Anhui Medical University 2025 Undergraduate Innovation Training Programme Approved Projects X202410366137, S202510366114, X202510366156Anhui Provincial Department of Education Scientific Research Project 2023AH053166Anhui Provincial Department of Education Scientific Research Project 2025AHGXZK40463Anhui Provincial Research Project on the Inheritance and Innovation of Traditional Chinese Medicine 2025CCCX164Department of Education of Anhui Province Outstanding Young Teacher Training Project YQZD2023023Natural Science Foundation of Anhui Province 2508085J050, 2508085MH195Natural Science Foundation of Anhui Province 2508085MH195the Doctoral research start-up foundation of the Second Affiliated Hospital of Anhui Medical University JF20250035The National Natural Science Foundation of China 82373932The Open project Fund of the Key Laboratory of Pharmaceutical Research and Clinical Evaluation of innovative Drugs in Anhui Province KFKT202402
6 · The paper itself

Abstract

backgroundLiver fibrosis is a representative scarring response that can ultimately lead to liver cancer. However, relevant antifibrotic drugs for the effective treatment of liver fibrosis in humans have not yet been identified. 6-Shogaol is derived from natural products and exhibits multiple biological activities, including anti-inflammatory and antioxidant properties; however, its efficacy and potential mechanism of action against liver fibrosis remains unclear. This study aimed to examine the anti-fibrotic properties and potential mechanisms of action of 6-Shogaol.

methodsTwo liver fibrosis mouse models (carbon tetrachloride (CCl

resultsThe results showed that 6-Shogaol remarkably alleviated CCl

conclusionThese findings showed that 6-Shogaol ameliorated liver fibrosis by modulating the expression of HIF-1α associated with glycolysis reprogramming and validate 6-Shogaol as a promising therapeutic strategy for liver fibrosis.

Indexed as

6-ShogaolGlycolysisHepatic stellate cellsLiver fibrosisNetwork pharmacology

Identifiers

PMID42204558
PMCPMC13214082

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.